Article

PDT developer seeks FDA approval for its drug for wet form of AMD

Miravant Medical Technologies is asking the FDA to okay a new drug application for marketing approval of its SnET2-PDT as a treatment for patients with wet form of age-related macular degeneration (AMD).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
John Saharek, president of ImprimisRX, speaks with Ophthalmology Times' David Hutton on three new products the company will be featuring during the American Academy of Ophthalmology's 2021 annual meeting
What keeps you up at night in ophthalmology: Part II
Chris Adams, Diopter Corp CEO
Ramin Valian, of Allergan, discusses pharmaceuticals in the glaucoma industry at Glaucoma 360
Related Content
FDA approves first biosimilar product for retinal diseases
August 5th 2025

Making the grade: FDA approves first biosimilar product for retinal diseases

Advancement in TED treatment is a bright spot
August 5th 2025

Advancement in TED treatment is a bright spot

Comparable conscious sedation methods address individual patient needs
August 5th 2025

Comparable conscious sedation methods address individual patient needs

Investigators uncover health care disparities among US patients
August 5th 2025

Investigators uncover health care disparities among US patients

Investigators zoom in on future of dry eye treatment
August 5th 2025

Investigators zoom in on future of dry eye treatment

Analyzing opioid prescription patterns of US retina specialists
August 5th 2025

Analyzing opioid prescription patterns of US retina specialists

© 2025 MJH Life Sciences

All rights reserved.